RNAC
Cartesian Therapeutics
$7.79
−$0.09 (−1.14%)Jul 27, 2026
Key metrics
The numbers that frame RNAC today
- Market cap
- $228.88M
- P/E (TTM)
- -1.5
- EV / FCF
- -1.6
- Gross margin
- 100%
- EV / Sales
- 68.8
- ROIC
- -107.4%
- Div yield
- 0%
- 52wk Low
- $5.60
- 52wk High
- $14.56
Growth
Revenue and earnings trend for RNAC
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about RNAC
Is Cartesian Therapeutics a good buy?
Hold. Cartesian Therapeutics has poor quality and mixed momentum. The setup is weak overall. Growth looks strong, which supports the long-term business case. We think Cartesian Therapeutics is selling at a very high price.
What is the market capitalization of RNAC?
Cartesian Therapeutics's market capitalization is $228.88M.
What is the P/E ratio for RNAC stock?
Cartesian Therapeutics's current P/E ratio is -1.5.
What is the 52-week high for RNAC stock?
The 52-week high for Cartesian Therapeutics is $14.56. The current close of $7.79 is 46.5% below that high.
What is the 52-week low for RNAC stock?
The 52-week low for Cartesian Therapeutics is $5.60. The current close of $7.79 is 39.1% above that low.
Does RNAC stock pay dividends?
Cartesian Therapeutics does not currently show a dividend per share in the company data.